| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
GSK8573 does not have a primary therapeutic target. It is an inactive control compound for GSK2801, which targets BAZ2A and BAZ2B bromodomains. GSK8573 has binding activity to BRD9 with a Kd of 1.04 μM but is inactive against BAZ2A/B and other bromodomain families. As a negative control, it is used to distinguish specific effects of GSK2801 from non-specific effects in bromodomain research.
|
|---|---|
| ln Vitro |
GSK8573 (1.0 μM) is inert against BAZ2A/B and other bromodomain families, but has binding activity to BRD9 with a Kd value of 1.04 μM [1].
GSK8573 is described as an inactive control compound. At 1.0 μM, it is inert against BAZ2A/B and other bromodomain families. It does, however, have binding activity to BRD9 with a Kd value of 1.04 μM. This weak binding to BRD9 is noted but the compound is considered inactive against its primary targets BAZ2A and BAZ2B. |
| ln Vivo |
GSK8573 is not a pharmacologically active compound and does not have defined in vivo activity. It is used as an inactive control in biological experiments to validate the specificity of GSK2801's effects. As a negative control, it helps researchers distinguish specific BAZ2A/B inhibition from non-specific effects in in vivo studies.
|
| Enzyme Assay |
GSK8573 does not have a defined in vitro assay protocol for enzyme or receptor binding as an active compound. Its binding activity to BRD9 (Kd = 1.04 μM) can be measured using standard bromodomain binding assays such as AlphaScreen, fluorescence polarization, or surface plasmon resonance (SPR). These assays are typically used to confirm its inactivity against BAZ2A/B and other bromodomain families.
|
| Cell Assay |
GSK8573 is not used in cell-based assays as an active pharmacological compound. It is used as a structurally related negative control compound in biological experiments. In cell-based assays, GSK8573 is typically included as a control to ensure that any observed effects of GSK2801 are due to BAZ2A/B inhibition rather than non-specific effects of the compound scaffold.
|
| Animal Protocol |
GSK8573 is not used in animal studies as a pharmacologically active compound. It is used as an inactive control compound in in vivo experiments to validate the specificity of GSK2801's effects. As a negative control, it helps researchers distinguish specific BAZ2A/B inhibition from non-specific effects in in vivo studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for GSK8573 are not relevant in a pharmacological context, as the compound is an inactive control rather than a therapeutic agent. The compound has a molecular weight of 323.39, a LogP of 4.44, and is soluble in DMSO at approximately 25 mg/mL. It is typically stored as a powder at -20°C for long-term stability.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for GSK8573 are not available, as the compound is an inactive control rather than a therapeutic agent. It is for research use only and is not for human use. As a negative control compound, it is not intended for therapeutic applications and its safety profile has not been comprehensively characterized for clinical use.
|
| References | |
| Additional Infomation |
GSK8573 is a research tool used as an inactive control compound for GSK2801, an acetyl-lysine competitive inhibitor of the BAZ2A and BAZ2B bromodomains. It has binding activity to BRD9 with a Kd of 1.04 μM but is inactive against BAZ2A/B and other bromodomain families. The compound can be used as a structurally related negative control (NC) compound in biological experiments. It was developed as a closely related structural analog and control compound for GSK2801. GSK8573 is not an approved therapeutic agent.
|
| Molecular Formula |
C20H21NO3
|
|---|---|
| Molecular Weight |
323.385645627975
|
| Exact Mass |
323.152
|
| CAS # |
1693766-04-9
|
| Related CAS # |
1693766-04-9 GSK8573
|
| PubChem CID |
121230107
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Index of Refraction |
1.569
|
| LogP |
4.44
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
24
|
| Complexity |
427
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCOC1=CC2=C(C=C(N2C=C1)C(=O)C)C3=CC(=CC=C3)OC
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~77.31 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.73 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0922 mL | 15.4612 mL | 30.9224 mL | |
| 5 mM | 0.6184 mL | 3.0922 mL | 6.1845 mL | |
| 10 mM | 0.3092 mL | 1.5461 mL | 3.0922 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
